Details of the Drug Combination

General Information of Drug Combination (ID: DCTNDHJ)

Drug Combination Name
Acamprosate Lacosamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Acamprosate   DMO381I Lacosamide   DMVM6QR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 12.69
Bliss Independence Score: 12.69
Loewe Additivity Score: 27.83
LHighest Single Agent (HSA) Score: 27.83

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Acamprosate
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [2]
Acamprosate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Agonist [5]
------------------------------------------------------------------------------------
Indication(s) of Lacosamide
Disease Entry ICD 11 Status REF
Convulsion 8A68.Z Approved [3]
Epilepsy 8A60-8A68 Approved [4]
Diabetic neuropathy 8C0Z Phase 3 [3]
Lacosamide Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A) TTN9VTF SCNBA_HUMAN Inhibitor [4]
Voltage-gated sodium channel (Nav) TTIG65Q NOUNIPROTAC Inhibitor [4]
Dihydropyrimidinase related protein 2 (DPYSL2) TTZCW3T DPYL2_HUMAN Modulator [6]
------------------------------------------------------------------------------------
Lacosamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7106).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7472).
4 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
5 Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
6 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
7 Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr. 2009 Sep-Oct;9(5):133-4.
8 Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.